PharmAkea gets funders, partner, potential acquirer in $45m Celgene-Bay City deal
This article was originally published in Scrip
Executive Summary
So long as its research goes as planned, PharmAkea's future is somewhat predictable now that the San Diego-based biopharmaceutical company has entered into a three-year, $35m funding and drug development agreement with Celgene.